2
|
Lu S, Zhang Y, Zhang G, Zhou J, Cang S, Cheng Y, Wu G, Cao P, Lv D, Jian H, Chen C, Jin X, Tian P, Wang K, Jiang G, Chen G, Chen Q, Zhao H, Ding C, Guo R, Sun G, Wang B, Jiang L, Liu Z, Fang J, Yang J, Zhuang W, Liu Y, Zhang J, Pan Y, Chen J, Yu Q, Zhao M, Cui J, Li D, Yi T, Yu Z, Yang Y, Zhang Y, Zhi X, Huang Y, Wu R, Chen L, Zang A, Cao L, Li Q, Li X, Song Y, Wang D, Zhang S, Ding L, Zhang L, Yuan X, Yao L, Shen Z. Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M mutated non-small cell lung cancer that had progressed after prior EGFR TKI therapy: A phase 2, multicenter, single-arm, open-label study. J Thorac Oncol 2022; 17:1192-1204. [PMID: 35724798 DOI: 10.1016/j.jtho.2022.06.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2022] [Revised: 06/05/2022] [Accepted: 06/09/2022] [Indexed: 02/05/2023]
Abstract
INTRODUCTION Befotertinib (D-0316) is a novel, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). This study evaluated befotertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who developed an EGFR T790M mutation after progression on first- or second-generation EGFR TKI therapy. METHODS This was a single-arm, open-label, phase 2 study at 49 hospitals across mainland China. Patients with locally advanced or metastatic NSCLC harboring EGFR T790M mutations with disease progression following prior first- or second- generation EGFR TKI therapy received oral befotertinib of 50 mg (cohort A) or 75-100 mg (cohort B) once daily. The primary endpoint was objective response rate (ORR) assessed by an independent review committee (IRC) in intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT03861156. RESULTS A total of 176 patients and 290 patients were included in cohorts A (50 mg) and B (75-100 mg), respectively. At data-cutoff (August 15, 2021), IRC-assessed ORR was 67.6% (95% confidence interval [CI]: 61.9%-72.9%) in cohort B. The investigator-assessed ORR was 54.0% (95% CI: 46.3%-61.5%) in cohort A and 65.9% (95% CI: 60.1%-71.3%) in cohort B. Investigator-assessed disease control rate was 93.2% (95% CI: 88.4%-96.4%) in cohort A and 94.8% (95% CI: 91.6%-97.1%) in cohort B. Investigator-assessed intracranial ORR was 26.7% (95% CI: 7.8%-55.1%) in cohort A and 57.1% (95% CI: 34.0%-78.2%) in cohort B. The median investigator-assessed progression-free survival (PFS) was 11.0 (95% CI: 9.6-12.5) months in cohort A and 12.5 (95% CI: 11.1-13.8) months in cohort B. The median investigator-assessed intracranial PFS was 16.5 (95% CI: 8.6-not evaluable [NE]) months in cohort A and NE (95% CI: 13.8-NE) in cohort B. The overall survival was immature. Grade 3 or higher treatment-related adverse events and treatment-related serious adverse events occurred in 20.5% and 11.4% of patients in cohort A, and in 29.3% and 10.0% of patients in cohort B, respectively. CONCLUSION Befotertinib of 75-100 mg has satisfying efficacy and manageable toxicity in patients with locally advanced or metastatic NSCLC harboring T790M mutation with resistance to first- or second- generation EGFR TKIs. A phase 3 randomized trial is underway (NCT04206072).
Collapse
Affiliation(s)
- Shun Lu
- Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
| | - Yiping Zhang
- Medical Department of Thoracic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, People's Republic of People's Republic of China
| | - Guojun Zhang
- Department of Respiratory Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China
| | - Jianying Zhou
- Department of Respiratory Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China
| | - Shundong Cang
- Department of Medical Oncology, Henan Provincial People's Hospital, Zhengzhou, People's Republic of China
| | - Ying Cheng
- Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, People's Republic of China
| | - Gang Wu
- Cancer Center, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People's Republic of China
| | - Peiguo Cao
- Department of Oncology, The Third Xiangya Hospital of Central South University, Changsha, People's Republic of China
| | - Dongqing Lv
- Department of Respiratory Medicine, Taizhou hospital of Zhejiang Province, Linhai, People's Republic of China
| | - Hong Jian
- Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China
| | - Chengshui Chen
- Department of Respiratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China
| | - Xiangming Jin
- Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China
| | - Panwen Tian
- Department of Respiratory and Critical Care Medicine, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, People's Republic of China
| | - Kai Wang
- Department of Respiratory Medicine, The Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, People's Republic of China
| | - Guanming Jiang
- Department of Medical Oncology, Dongguan People's Hospital, Dongguan, People's Republic of China
| | - Gongyan Chen
- Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China
| | - Qun Chen
- Department of Oncology, Fuzhou Pulmonary Hospital of Fujian, Fuzhou, People's Republic of China
| | - Hui Zhao
- Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China
| | - Cuimin Ding
- Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University and Hebei Cancer Hospital, Shijiazhuang, People's Republic of China
| | - Renhua Guo
- Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China
| | - Guoping Sun
- Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China
| | - Bin Wang
- Department of Respiratory Medicine, Huzhou Central Hospital, Huzhou, People's Republic of China
| | - Liyan Jiang
- Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China
| | - Zhe Liu
- Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Jian Fang
- Department of Thoracic Oncology, Peking University Cancer Hospital, Beijing Cancer Hospital, Beijing, People's Republic of China
| | - Junquan Yang
- Department of Radiotherapy and Chemotherapy, Tangshan People's Hospital, Tangshan, People's Republic of China
| | - Wu Zhuang
- Department of Thoracic Oncology, Fujian Cancer Hospital, Fuzhou, People's Republic of China
| | - Yunpeng Liu
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, People's Republic of China
| | - Jian Zhang
- Department of Respiratory Medicine, Air Force Medical University of PLA, the Fourth Military Medical University, Xi'an, People's Republic of China
| | - Yueyin Pan
- Department of Medical Oncology/Chemotherapy, The First Affiliated Hospital of University of Science and Technology of China, Anhui Provincial Hospital, Hefei, People's Republic of China
| | - Jun Chen
- Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, People's Republic of China
| | - Qitao Yu
- Department of Respiratory Oncology, The Guangxi Medical University Cancer Hospital, Guangxi Cancer Hospital, Nanning, People's Republic of China
| | - Min Zhao
- Department of Oncology, Hebei Chest Hospital, Shijiazhuang, People's Republic of China
| | - Jiuwei Cui
- Cancer Center, The First Hospital of Jilin University, Changchun, People's Republic of China
| | - Dianming Li
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical College, Bengbu, People's Republic of China
| | - Tienan Yi
- Department of Oncology, Xiangyang Central Hospital, Xiangyang, People's Republic of China
| | - Zhuang Yu
- Department of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China
| | - Yan Yang
- Department of Oncology, Chifeng Municipal Hospital, Chifeng, People's Republic of China
| | - Yan Zhang
- Department of Oncology, Shijiazhuang People's Hospital, Shijiazhuang, People's Republic of China
| | - Xiuyi Zhi
- Department of Thoracic Surgery, Xuanwu Hospital Affiliated to Capital Medical University, Beijing, People's Republic of China
| | - Yunchao Huang
- Department of Thoracic Surgery, Yunnan Cancer Hospital/the Third Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China
| | - Rong Wu
- Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, People's Republic of China
| | - Liangan Chen
- Department of Respiratory Medicine, The First Medical Centre of Chinese PLA General Hospital, Beijing, People's Republic of China
| | - Aimin Zang
- Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, People's Republic of China
| | - Lejie Cao
- Department of Respiratory Medicine, The First Affiliated Hospital of University of Science and Technology of China, Anhui Provincial Hospital, Hefei, People's Republic of China
| | - Qingshan Li
- Department of Medical Oncology, Affiliated Hospital of Chengde Medical College, Chengde, People's Republic of China
| | - Xiaoling Li
- Department of Thoracic Cancer, Liaoning Cancer Hospital & Institute, Shenyang, People's Republic of China
| | - Yong Song
- Department of Respiratory Medicine, Jinling Hospital Nanjing University School of Medicine, Nanjing, People's Republic of China
| | - Donglin Wang
- Department of Medical Oncology, Cancer Hospital Affiliated to Chongqing University, Chongqing Cancer Hospital, Chongqing, People's Republic of China
| | - Shucai Zhang
- Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Lieming Ding
- Betta Pharmaceuticals Co., Ltd., Hangzhou, People's Republic of China
| | - Ling Zhang
- InventisBio Co., Ltd., Shanghai, People's Republic of China
| | - Xiaobin Yuan
- Betta Pharmaceuticals Co., Ltd., Hangzhou, People's Republic of China
| | - Lin Yao
- Betta Pharmaceuticals Co., Ltd., Hangzhou, People's Republic of China
| | - Zhilin Shen
- Betta Pharmaceuticals Co., Ltd., Hangzhou, People's Republic of China
| |
Collapse
|